Keystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for solid tumors. Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that […]
Keystone Nano
Keystone Nano wins FDA nod for nanoliposome cancer treatment
Keystone Nano said today that the FDA approved its investigational new drug application for the ceramide nanoliposome as a treatment for solid tumors. The company will launch a phase I trial at 3 sites to evaluate safe dosing levels and the product’s efficacy as a cancer therapy. Ceramide is a lipid that has demonstrated efficacy in […]
Keystone Nano wins orphan designation for ceramide liver cancer treatment
Keystone Nano said today that its ceramide nanoliposome won orphan drug status from the FDA for the treatment of liver cancer. The designation provides the company with a window of market exclusivity after product approval. The State College, Penn.-based company touted its nanoliposome delivery system as being able to load both water-loving and water-hating compounds and […]
